Fate Therapeutics, a La Jolla, CA-based biotech startup tapping advances in stem cell biology to develop new drugs, says it has gained exclusive rights to technology involving blood-forming stem cells from Children’s Hospital Boston and Massachusetts General Hospital. The hospitals jointly own the technology. Leonard Zon, director of the stem cell program at Children’s and a scientific founder of Fate, developed the stem cell technology. Randall Moon, a stem cell expert at the University of Washington, is another of several scientific founders of Fate.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
